Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023

We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]

Colin Hill Keynote at Servier Paris-Saclay R&D Institute in France

On July 20th, we had the privilege to visit the cutting-edge Servier Paris-Saclay R&D Institute in France, where our CEO, Colin Hill delivered a keynote titled: “Why AI and Digital Twins will Drive the Discovery and Development of the Next Generation of Breakthrough Drugs“. The open conference was a remarkable display of Servier’s dedication to foster a collaborative […]

Alzheimer’s Disease Mechanistic Pathways Discovered through Aitia’s Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023

We are delighted to announce that Aitia will be at the upcoming Alzheimer’s Association International Conference (AAIC) being held from July 16-20 in Amsterdam, Netherlands. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on Bayesian […]